Skip to main content
×
×
Home

GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder

  • Chih-Ken Chen (a1), Chau-Shoun Lee (a2), Hsuan-Yu Chen (a3), Lawrence Shih-Hsin Wu (a4), Jung-Chen Chang (a5), Chia-Yih Liu (a6) and Andrew Tai-Ann Cheng (a7)...
Abstract
Background

Genetic variants and medication adherence have been identified to be the main factors contributing to lithium treatment response in bipolar disorders.

Aims

To simultaneously examine effects of variant glutamate decarboxylase-like protein 1 (GADL1) and medication adherence on response to lithium maintenance treatment in Han Chinese patients with bipolar I (BPI) disorder.

Method

Frequencies of manic and depressive episodes between carriers and non-carriers of the effective GADL1 rs17026688 T allele during the cumulative periods of off-lithium, poor adherence to lithium treatment and good adherence to lithium treatment were compared in Han Chinese patients with BPI disorder (n = 215).

Results

GADL1 rs17026688 T carriers had significantly lower frequencies of recurrent affective episodes than non-T carriers during the cumulative period of good adherence, but not during those of poor adherence.

Conclusions

GADL1 rs17026688 and medication adherence jointly predict response to lithium maintenance treatment in Han Chinese BPI patients.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder
      Available formats
      ×
Copyright
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Corresponding author
Andrew Tai-Ann Cheng, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Email: bmandrew@gate.sinica.edu.tw
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Geddes, JR, Goodwin, GM, Rendell, J, Azorin, JM, Cipriani, A, Ostacher, MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385–95.
2 Rybakowski, JK, Chlopocka-Wozniak, M, Suwalska, A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord 2001; 3: 63–7.
3 Garnham, J, Munro, A, Slaney, C, Macdougall, M, Passmore, M, Duffy, A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007; 104: 185–90.
4 Kleindienst, N, Engel, RR, Greil, W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med 2005; 35: 1685–94.
5 Kleindienst, N, Engel, R, Greil, W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005; 7: 404–17.
6 Berghofer, A, Alda, M, Adli, M, Baethge, C, Bauer, M, Bschor, T, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry 2008; 69: 1860–8.
7 Rybakowski, JK. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs 2013; 27: 165–73.
8 Perlis, RH, Smoller, JW, Ferreira, MA, McQuillin, A, Bass, N, Lawrence, J, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166: 718–25.
9 Chen, CH, Lee, CS, Lee, MT, Ouyang, WC, Chen, CC, Chong, MY, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370: 119–28.
10 DiMatteo, MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–9.
11 Haynes, RB, McDonald, HP, Garg, AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880–3.
12 Osterberg, L, Blaschke, T. Adherence to medication. N Eng J Med 2005; 353: 487–97.
13 Julius, RJ, Novitsky, MA Jr., Dubin, WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009; 15: 3444.
14 Colom, F, Vieta, E, Martinez-Aran, A, Reinares, M, Benabarre, A, Gasto, C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000; 61: 549–55.
15 Murru, A, Pacchiarotti, I, Amann, BL, Nivoli, AM, Vieta, E, Colom, F. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord 2013; 151: 1003–8.
16 Connelly, CE, Davenport, YB, Nurnberger, JI Jr. Adherence to treatment regimen in a lithium carbonate clinic. Arch Gen Psychiatry 1982; 39: 585–8.
17 Malhotra, AK, Zhang, JP, Lencz, T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012; 17: 760–9.
18 Lee, MT, Chen, CH, Lee, CS, Chen, CC, Chong, MY, Ouyang, WC, et al. Genome-wide association study of bipolar I disorder in the Han Chinese population. Mol Psychiatry 2011; 16: 548–56.
19 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. APA, 1994.
20 Cheng, ATA, Tien, AY, Chang, CJ, Brugha, TS, Cooper, JE, Lee, CS, et al. Cross-cultural implementation of a Chinese version of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) in Taiwan. Br J Psychiatry 2001; 178: 567–72.
21 Yang, YY. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand 1985; 71: 171–5.
22 Kane, JM, Leucht, S, Carpenter, D, Docherty, JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 (suppl 12): 519.
23 Hou, L, Heilbronner, U, Rietschel, M, Kato, T, Kuo, PH, McMahon, FJ, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med 2014; 370: 1857–9.
24 Ikeda, M, Kondo, K, Iwata, N. Variant GADL1 and response to lithium in bipolar I disorder. N Eng J Med 2014; 370: 1856–7.
25 Kotambail, A, Mathur, A, Bhat, SM, Rai, PS, Sharma, PS, Satyamoorthy, K. GADL1 gene polymorphisms and lithium response in bipolar I disorder: lack of association from an Indian population. Psychiatr Genet 2015; 25: 3940.
26 Cruceanu, C, Alda, M, Dion, PA, Turecki, G, Rouleau, GA. No evidence for GADL1 variation as a bipolar disorder susceptibility factor in a Caucasian lithium-responsive cohort. Am J Psychiatry 2015; 172: 94–5.
27 Gonzalez-Pinto, A, Mosquera, F, Alonso, M, López, P, Ramírez, F, Vieta, E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006; 8: 618–24.
28 dbSNP Short Genetic Variations: rs1702668 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs17026688).
29 dbSNP Short Genetic Variations: rs17026651 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs17026651).
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder

  • Chih-Ken Chen (a1), Chau-Shoun Lee (a2), Hsuan-Yu Chen (a3), Lawrence Shih-Hsin Wu (a4), Jung-Chen Chang (a5), Chia-Yih Liu (a6) and Andrew Tai-Ann Cheng (a7)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *